Methylmalonic acidemia, also called methylmalonic aciduria,[note 1] is an autosomal recessive metabolic disorder that disrupts normal amino acid metabolism. It is a classical type of organic acidemia. The result of this condition is the inability to properly digest specific fats and proteins, which in turn leads to a buildup of a toxic level of methylmalonic acid in the blood.
Methylmalonic acidemia stems from several genotypes, all forms of the disorder usually diagnosed in the early neonatal period, presenting progressive encephalopathy, and secondary hyperammonemia. The disorder can result in death if undiagnosed or left untreated. It is estimated that this disorder has a frequency of 1 in 48,000 births, though the high mortality rate in diagnosed cases make exact determination difficult. Methylmalonic acidemias are found with an equal frequency across ethnic boundaries.
Symptoms and signs
Depending on the affected gene(s), this disorder may present symptoms that range from mild to life-threatening.
- Progressive encephalopathy
- Kidney failure
- Failure to thrive and developmental delays
- Repeated yeast infections
- Respiratory distress
- Low red blood cell, white blood cell, and platelet concentrations
The inherited forms of methylmalonic acidemia cause defects in the metabolic pathway where methylmalonyl-coenzyme A (CoA) is converted into succinyl-CoA by the enzyme methylmalonyl-CoA mutase.
Vitamin B12 is also needed for the conversion of methylmalonyl-CoA to succinyl-CoA. Mutations leading to defects in vitamin B12 metabolism or in its transport frequently result in the development of methylmalonic acidemia.
This disorder has an autosomal recessive inheritance pattern, which means the defective gene is located on an autosome, and two copies of the gene—one from each parent—must be inherited to be affected by the disorder. The parents of a child with an autosomal recessive disorder are carriers of one copy of the defective gene, but are usually not affected by the disorder.
Though not always grouped together with the inherited versions, a severe nutritional deficiency of vitamin B12 can also result in syndrome with identical symptoms and treatments as the genetic methylmalonic acidemias. Methylmalonyl-CoA requires vitamin B12 to form succinyl-CoA. When the amount of B12 is insufficient for the conversion of cofactor methylmalonyl-CoA into succinyl-CoA, the buildup of unused methylmalonyl-CoA eventually leads to methylmalonic acidemia. This diagnosis is often used as an indicator of vitamin B12 deficiency in serum.
In methylmalonic acidemia, the body is unable to break down the amino acids methionine, threonine, isoleucine and valine; as a result methylmalonic acid builds up in the blood and tissues. Those afflicted with this disorder are either lacking functional copies or adequate levels of one or more of the following enzymes: methylmalonyl-CoA mutase, methylmalonyl-CoA epimerase, or those involved in adenosylcobalamin synthesis.
It is estimated that as many as 60% of cases are the result of a mutated MUT gene which encodes the protein methylmalonyl-CoA mutase. This enzyme is responsible for the digestion of potentially toxic derivatives of the breakdown of the above-mentioned amino acids and fats, primarily cholesterol, particularly this enzyme converts methylmalonyl-CoA into succinyl-CoA. Without this enzyme, the body has no means to neutralize or remove methylmalonic acid and related compounds. The action of this enzyme can also be crippled by mutations in the MMAA, MMAB, and MMADHC genes, each of which encodes a protein required for normal functioning of methylmalonyl-CoA mutase.
Mutations in the MCEE gene, which encodes the methylmalonyl-CoA epimerase protein, also referred to as methylmalonyl racemase, will cause a much more mild form of the disorder than the related methylmalonyl-CoA mutase variant. Like the mutase, the epimerase also functions in breaking down the same substances, but to a significantly lesser extent than the mutase does. The phenotypic differences caused by a deficiency of the epimerase as opposed to the mutase are so mild that there is debate within the medical community as to whether or not this genetic deficiency can be considered a disorder or clinical syndrome.
Also known as vitamin B12, this form of cobalamin is a required cofactor of methylmalonyl-CoA mutase. Even with a functional version of the enzyme at physiologically normal levels, if B12 cannot be converted to this active form, the mutase will be unable to function.
Though there are not distinct stages of the disease, methylmalonic acidemia is a progressive condition; the symptoms of this disorder are compounded as the concentration of methylmalonic acid increases. If the triggering proteins and fats are not removed from the diet, this buildup can lead to irreparable kidney or liver damage and eventually death.
One of, if not the most common form of organic acidemia, methylmalonic acidemia is not apparent at birth as symptoms usually do not present themselves until proteins are added to the infant's diet. Because of this, symptoms typically manifest anytime within the first year of life. Due to the severity and rapidity in which this disorder can cause complications when left undiagnosed, screening for methylmalonic acidemia is often included in the newborn screening exam.
Because of the inability to properly break down amino acids completely, the byproduct of protein digestion, the compound methylmalonic acid, is found in a disproportionate concentration in the blood and urine of those afflicted. These abnormal levels are used as the main diagnostic criteria for diagnosing the disorder. This disorder is typically determined through the use of a urine analysis or blood panel. The presence of methylmalonic acidemia can also be suspected through the use of a CT or MRI scan or ammonia test, however these tests are by no means specific and require clinical and metabolic/correlation. Elevated levels of ammonia, glycine, and ketone bodies may also be present in the blood and urine.
Methylmalonic acidemia has varying diagnoses, treatment requirements and prognoses, which are determined by the specific genetic mutation causing the inherited form of the disorder. The following are the known genotypes responsible for methylmalonic acidemia:
|Online Mendelian Inheritance in Man (OMIM) 251100||cblA type||MMAA|
|Online Mendelian Inheritance in Man (OMIM) 251110||cblB type||MMAB|
|Online Mendelian Inheritance in Man (OMIM) 277400||cblC type||MMACHC|
|Online Mendelian Inheritance in Man (OMIM) 277410||cblD type||MMADHC|
|Online Mendelian Inheritance in Man (OMIM) 277380||cblF type||LMBRD1|
|Online Mendelian Inheritance in Man (OMIM) 251000||mut type||MUT|
The mut type can further be divided into mut0 and mut- subtypes, with mut0 characterized by a complete lack of methylmalonyl-CoA mutase and more severe symptoms and mut- characterized by a decreased amount of mutase activity.
Mut-, cblB, and cblA versions of methylmalonic acidemia have been found to be cobalamin responsive. Mut0 is a nonresponsive variant.
Treatment for all forms of this condition primarily relies on a low-protein diet, and depending on what variant of the disorder the individual suffers from, various dietary supplements. All variants respond to the levo isomer of carnitine as the improper breakdown of the affected substances results in sufferers developing a carnitine deficiency. The carnitine also assists in the removal of acyl-CoA, buildup of which is common in low-protein diets by converting it into acyl-carnitine which can be excreted in urine. Some forms of methylmalonyl acidemia are responsive to cobalamin although cyanocobalamin supplements could prove detrimental to some forms.  If the individual proves responsive to both cobalamin and carnitine supplements, then it may be possible for them to ingest substances that include small amounts of the problematic amino acids isoleucine, threonine, methionine, and valine without causing an attack.
A more extreme treatment includes kidney or liver transplant from a donor without the condition. The foreign organs will produce a functional version of the defective enzymes and digest the methylmalonic acid, however all of the disadvantages of organ transplantation are of course applicable in this situation. There is evidence to suggest that the central nervous system may metabolize methylmalonyl-CoA in a system isolated from the rest of the body. If this is the case, transplantation may not reverse the neurological effects of methylmalonic acid previous to the transplant or prevent further damage to the brain by continued build up.
The prognosis will vary depending on the severity of the condition and the individual's response to treatment. Prognosis is typically better for those with cobalamin-responsive variants and not promising in those suffering from noncobalamin-responsive variants. Milder variants have a higher frequency of appearance in the population than the more severe ones. Even with dietary modification and continued medical care, it may not be possible to prevent neurological damage in those with a nonresponsive acidemia. Without proper treatment or diagnosis, it is not uncommon for the first acidemic attack to be fatal.
Despite these challenges, since it was first identified in 1967, treatment and understanding of the condition has improved to the point where it is not unheard of for even those with unresponsive forms of methylmalonic acidemia to be able to reach adulthood and even carry and deliver children safely.
MMA was first characterized by Oberholzer et al. in 1967.
That MMA can have disastrous effects on the nervous system has been long reported; however, the mechanism by which this occurs has never been determined. Published on June 15, 2015, research performed on the effects of methylmalonic acid on neurons isolated from fetal rats in an in vitro setting using a control group of neurons treated with an alternate acid of similar pH. These tests have suggested that methylmalonic acid causes decreases in cellular size and increase in the rate of cellular apoptosis in a concentration dependent manner with more extreme effects being seen at higher concentrations. Furthermore, micro-array analysis of these treated neurons have also suggested that on an epigenetic-level methylmalonic acid alters the transcription rate of 564 genes, notably including those involved in the apoptosis, p53, and MAPK signaling pathways.
As the conversion of methylmalonyl-CoA to succinyl-CoA takes place inside the mitochondria, mitochondrial dysfunction as a result of diminished electron transport chain function has long been suspected as a feature in MMA. Recent research has found that in rat models mitochondria of rats affected by the disorder grow to unusual size, dubbed megamitochondria. These megamitochondria also appear to have deformed internal structures and a loss in electron richness in their internal matrix. These megamitochondria also showed signs of decreased respiratory chain function, particularly in respiratory complex IV which only functioned at about 50% efficiency. Similar changes were identified in the mitochondria of a liver sample removed during transplant from a 5-year-old boy suffering from MMA.
Benign mut phenotype
Recent case studies in several patients presenting nonresponsive mut0 MMA with a specific mutation designated p.P86L have suggest the possibility of further subdivision in mut type MMA might exist. Though currently unclear if this is due to the specific mutation or early detection and treatment, despite complete nonresponse to cobalamin supplements, these individuals appeared to develop a largely benign and near completely asymptomatic version of MMA. Despite consistently showing elevated methylmalonic acid in the blood and urine, these individuals appeared for the large part developmentally normal.
- Ryan Stallings, a St. Louis infant, was mistakenly diagnosed with ethylene glycol poisoning instead of MMA in 1989, leading to a wrongful murder conviction and life sentence for his mother, Patricia Stallings.
- Combined malonic and methylmalonic aciduria (CMAMMA)
- Isovaleric acidemia
- Propionic acidemia
- Maple syrup urine disease
- ↑ The names methylmalonic acidemia and methylmalonic aciduria, which are also sometimes written as solid compounds (methylmalonicacidemia and methylmalonicaciduria), use the suffixes -emia and -uria and literally mean "[excess] methylmalonic acid in the blood" and "[excess] methylmalonic acid in the urine", respectively; they are used to label both the fluid analysis findings and the disease entity that causes them.
- ↑ Radmanesh, A; Zaman, T; Ghanaati, H; Molaei, S; Robertson, Rl; Zamani, Aa (July 2008). "Methylmalonic acidemia: brain imaging findings in 52 children and a review of the literature". Pediatric Radiology 38 (10): 1054–61. doi:10.1007/s00247-008-0940-8. PMID 18636250.
- ↑ "MMA Study: FAQ About Our Study". genome.gov. http://www.genome.gov/19016901.
- ↑ "Classical organic acidurias, propionic aciduria, methylmalonic aciduria, and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry". J Inherit Metab Dis 29 (2–3): 383–389. 2006. doi:10.1007/s10545-006-0278-z. PMID 16763906.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 "Methylmalonic acidemia". MedlinePlus Medical Encyclopedia. US National Library of Medicine. https://www.nlm.nih.gov/medlineplus/ency/article/001162.htm. Retrieved 2015-10-27.
- ↑ 5.0 5.1 Matsui, Sm; Mahoney, Mj; Rosenberg, Le (April 1983). "The natural history of the inherited methylmalonic acidemias" (Free full text). The New England Journal of Medicine 308 (15): 857–61. doi:10.1056/NEJM198304143081501. ISSN 0028-4793. PMID 6132336. http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+68-19-9.
- ↑ 6.0 6.1 6.2 "MMA Study: General Information". http://www.genome.gov/19016900.
- ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 "Acidemia, Methylmalonic". NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/acidemia-methylmalonic/.
- ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 8.10 8.11 8.12 "Methylmalonic acidemia". Genetics Home Reference. US National Library of Medecine. 2015-10-26. http://ghr.nlm.nih.gov/condition/methylmalonic-acidemia.
- ↑ "Mutation and haplotype analyses of the MUT gene in Japanese patients with methylmalonic acidemia". Journal of Human Genetics 52 (1): 48–55. 2007. doi:10.1007/s10038-006-0077-2. PMID 17075691.
- ↑ "A syndrome of methylmalonic aciduria, homocystinuria, megaloblastic anemia and neurological abnormalities in a vitamin B12-deficient breast-fed infant of a strict vegetarian". N Engl J Med 299 (7): 317–323. 1978. doi:10.1056/NEJM197808172990701. PMID 683264.
- ↑ http://www.biology.arizona.edu/biochemistry/problem_sets/b12/04t.html
Vitamin B12 deficiency - The methylmalonic aciduria connection
- ↑ 12.0 12.1 12.2 12.3 Methylmalonic Acidemia at eMedicine
- ↑ Online Mendelian Inheritance in Man (OMIM) Methylmalonyl-CoA Epimerase Deficiency -251120
- ↑ 14.0 14.1 14.2 14.3 Saini, N (March 2015). "Methylmalonic acidemia mimicking diabetic ketoacidosis and septic shock in infants". Indian Journal of Critical Care Medicine 19 (3): 183–185. doi:10.4103/0972-5229.152776. PMID 25810618.
- ↑ Kimberly G Lee. "Newborn screening tests". MedlinePlus Medical Encyclopedia. Division of Neonatology, Medical University of South Carolina. https://www.nlm.nih.gov/medlineplus/ency/article/007257.htm. Retrieved April 26, 2016.
- ↑ "Gene identification for the cblD defect of vitamin B12 metabolism". N Engl J Med 358 (14): 1454–64. 2008. doi:10.1056/NEJMoa072200. PMID 18385497. http://bura.brunel.ac.uk/handle/2438/2854.
- ↑ "Identification of a putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B12 metabolism". Nat Genet 41 (2): 234–9. Feb 2009. doi:10.1038/ng.294. PMID 19136951.
- ↑ "Therapeutic misuse of cyanocobalamin". Lancet 2 (8098): 1053–1054. November 1978. doi:10.1016/s0140-6736(78)92379-6. PMID 82069.
- ↑ 19.0 19.1 19.2 19.3 Online Mendelian Inheritance in Man (OMIM) Methylmalonic Aciduria due to Methylmalonyl-CoA Mutase deficiency -251000
- ↑ "Methylmalonic aciduria. An inborn error of metabolism leading to chronic metabolic acidosis". Arch Dis Child 42 (225): 492–504. 1967. doi:10.1136/adc.42.225.492. PMID 6061291.
- ↑ Han, L. (Jun 15, 2015). "Insights into the molecular mechanisms of methylmalonic acidemia using microarray technology". International Journal of Clinical and Experimental Medicine 8 (6): 8866–8879. PMID 26309541.
- ↑ Chandler, Randy j. (December 16, 2008). "Mitochondrial dysfunction in mut methylmalonic acidemia". The FASEB Journal 23 (4): 1252–1261. doi:10.1096/fj.08-121848. PMID 19088183.
- ↑ Underhill, H (December 2013). "Asymptomatic methylmalonic acidemia in a homozygous MUT mutation (p.P86L)". Pediatrics International 55 (6): e156-8. doi:10.1111/ped.12195. PMID 24330302.
- "Isolated Methylmalonic Acidemia". GeneReviews® [Internet] (University of Washington). 2016. NBK1231. PMID 20301409. https://pubmed.ncbi.nlm.nih.gov/20301409/.
- "Disorders of Intracellular Cobalamin Metabolism". GeneReviews® [Internet] (University of Washington). 2021. NBK1328. PMID 20301503. https://pubmed.ncbi.nlm.nih.gov/20301503/.
Original source: https://en.wikipedia.org/wiki/Methylmalonic acidemia. Read more